Infantile tauopathies: Hemimegalencephaly; tuberous sclerosis complex; focal cortical dysplasia 2; ganglioglioma

Brain and Development

Volumn 37, Issue 6, 2015, Pages 553-562

  Sarnat, Harvey B ^a   Flores Sarnat, Laura ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Epidermal naevus syndromes; Epilepsy; Everolimus; Focal cortical dysplasia type 2; Ganglioglioma; Hemimegalencephaly; Infantile tauopathies; MTOR pathway; Postzygotic somatic mosaicism; Proteus syndrome; Tuberous sclerosis complex

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MICROTUBULE ASSOCIATED PROTEIN; MAPT PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TAU PROTEIN;

ALEXANDER DISEASE; CELL CYCLE; CELL DIFFERENTIATION; CELL GROWTH; CELL MIGRATION; CORTICAL DYSPLASIA; GLIOMA; HUMAN; INFANT; INFANT DISEASE; MICROTUBULE; MITOSIS SPINDLE; MOSAICISM; NERVE CELL DEGENERATION; NERVE FIBER TRANSPORT; NEUROEPITHELIUM; NEVUS; PHAKOMATOSIS; PROTEIN PHOSPHORYLATION; REVIEW; SOMATIC MUTATION; TAUOPATHY; TUBEROUS SCLEROSIS; UPREGULATION; BRAIN; COMPLICATION; EPILEPSY; GENETICS; MALE; MALFORMATION OF CORTICAL DEVELOPMENT GROUP I; METABOLISM; NERVE CELL; PATHOLOGY; PHOSPHORYLATION;

BRAIN; EPILEPSY; GANGLIOGLIOMA; HEMIMEGALENCEPHALY; HUMANS; INFANT; MALE; MALFORMATIONS OF CORTICAL DEVELOPMENT, GROUP I; MICROTUBULES; NEURONS; PHOSPHORYLATION; TAU PROTEINS; TAUOPATHIES; TOR SERINE-THREONINE KINASES; TUBEROUS SCLEROSIS;

EID: 84928303405     PISSN: 03877604     EISSN: 18727131     Source Type: Journal    
DOI: 10.1016/j.braindev.2014.08.010     Document Type: Review

References (109)

1. Mackenzie I.R., Neumann M., Cairns N.J., Muñoz D.G., Isaacs A.M. Novel types of frontotemporal lobar degeneration: beyond tau and TDP-43. J Mol Neurosci 2011, 45:402-408.
2. Irwin D.J., Cohen T.J., Grossman M., Arnold S.E., Xie S.X., Lee V.M.-Y., et al. Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies. Brain 2012, 135:807-818.
3. Takashima S., Chan F., Becker L.E., Kuruta H. Aberrant neuronal development in hemimegalencephaly: immunohistochemical and Golgi studies. Paediatr Neurol 1991, 7:275-280.
4. Yasha T.C., Santosh V., Das S., Shankar S.K. Hemimegalencephaly: morphological and immunocytochemical study. Clin Neuropathol 1997, 1997(16):17-22.
5. Flores-Sarnat L., Sarnat H.B., Dávila-Gutiérrez G., Álvarez A. Hemimegalencephaly: part 2. Neuropathology suggests a disorder of cellular lineage. J Child Neurol 2003, 18:776-785.
6. Flores-Sarnat L. Hemimegalencephaly syndrome. In: Sarnat HB, Curatolo P, editors. Handbook of clinical neurology: malformations of the nervous system, vol. 87, 3rd series. Edinburgh, London, NY, Toronto: Elsevier; 2008. p. 153-76.
7. O'Kusky J.R., Akers M.-A., Vinters H.V. Synaptogenesis in hemimegalencephaly: the numerical density of asymmetric and symmetric synapses in the cerebral cortex. Acta Neuropathol 1996, 92:156-163.
8. Sakuta R., Aikawa H., Takashima S., Ryo S. Epidermal nevus syndrome with hemimegalencephaly. Neuropathological study. Brain Dev 1994, 13:260-265.
9. Flores-Sarnat L. Hemimegalencephaly: part 1. Genetic, clinical and imaging aspects. J Child Neurol 2002, 17:373-384.
10. Flores-Sarnat L. Hemimegalencephaly syndrome. In: Handbook of clinical neurology. Sarnat HB, Curatolo P, editors. Malformations of the nervous system, vol. 87. Edinburgh: Elsevier; 2008. p. 153-76.
11. Flores-Sarnat L. Epidermal nevus syndrome. In: Dulac O, Lassonde M, Sarnat HB, editors. Elsevier handbook of clinical neurology: paediatric neurology, vol. 111, 3rd series. Edinburgh, London, NY, Toronto: Elsevier; 2013. p. 349-68.
12. Lindhurst M.J., Sapp J.C., Teer J.K., Johnston J.J., Finn E.M., Peters K., et al. A mosaic activating mutation in AKT1 associated with Proteus syndrome. N Engl J Med 2011, 365:611-619.
13. Lee J.H., Huynh M., Silhavy J.L., Kim S., Dixon-Salazar T., Heiberg A., et al. De novo somatic mutations in components of the P13K-AKT3-mTOR pathway cause hemimegalencephaly. Nat Genet 2012, 44:941-945.
14. Poduri A., Evrony G.D., Cai X., Elhosary P.C., Beroukhim R., Lehtinen M.K., et al. Somatic activation of AKT3 causes hemispheric developmental brain malformations. Neuron 2012, 74:41-48.
15. Baek S.T., Gibbs E.M., Gleeson J.G., Mathern G.W. Hemimegalencephaly, a paradigm for somatic postzygotic neurodevelopmental disorders. Curr Opin Neurol 2013, 26:122-127.
16. Poduri A., Evrony G.D., Cai X., Walsh C.A. Somatic mutation, genomic variation, and neurologic disease. Science 2013, 2013(341):1237758.
17. Ávila J, Gómez de Barreda E, Fuster-Matanzo A, Simón D, Llorens-Martín M, Engel T, et al. Looking for novel functions of tau. Biochem Soc Trans 2012;40:653-5.
18. Sarnat H.B., Flores-Sarnat L., Crino P.B., Hader W., Bello-Espinosa L. Hemimegalencephaly: foetal tauopathy with mTOR hyperactivation and neuronal lipidosis. Folia Neuropathol 2012, 50:330-345.
19. Oblak A, Murrell J, Richardson R, Epperson F, Ghetti B. Comparative analysis of neuronal vulnerability of the anterior cingulate cortex in hereditary and sporadic tauopathies. J Neuropathol Exp Neurol 2014;73:597 (abstract).
20. European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 1993;75:1305-15.
21. Van Slegtenhorst M.M., de Hoogt R., Hermans C., Nellist M., Janssen B., Verhoef S., et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997, 277:805-808.
22. Curatolo P., Bombardieri R., Jozwiak S. Tuberous sclerosis. Lancet 2008, 372:657-668.
23. Curatolo P, Bombardieri R. Tuberous sclerosis. In: Sarnat, HB, Curatolo P, editors. Handbook of clinical neurology: malformations of the nervous system, vol. 87, 3rd series. Edinburgh, London, NY, Toronto: Elsevier; 2008. p 129-51.
24. Nellist M., van Slegtenhorst M.A., Goedbloed M., van den Ouweland A.M., Halley D.J., van der Sluijs P. Characterization of the cytosolic tuberin-hamartin complex. Tuberin is a cytosolic chaperone for hamartin. J Biol Chem 1999, 274:35647-35652.
25. Vinters HV, Kerfoot C, Catania M, Emelin JK, Roper SN, DeClue JE, et al. Tuberous sclerosis-related gene expressions in normal and dysplastic brain. Epilepsy Res 1998;32:12-23.
26. Johnson M.W., Emelin J.K., Park S.H., Vinters H.V. Co-localization of TSC1 and TSC2 gene products in tubers of patients with tuberous sclerosis. Brain Pathol 1999, 9:45-54.
27. Park S.H., Pepkowitz S.H., Kerfoot C., De Rosa M.J., Poukens V., Wienecke R., et al. Tuberous sclerosis in a 20-week gestation fetus: immunocytochemical study. Acta Neuropathol 1997, 94:180-186.
28. Prabowo A.S., Anink J., Lammens M., Nellist M., van den Ouweland A.M.W., Adle-Biassette H., et al. Fetal brain lesions in tuberous sclerosis complex: TORC1 activation and inflammation. Brain Pathol 2013, 23:45-59.
29. Tsai V., Parker W., Orlova K.A., Baybis M., Chi A.W.S., Berg B.D., et al. Fetal brain mTOR signaling pathway activation in tuberous sclerosis complex. Cereb Cortex 2014, 24:315-327.
30. Jóźwiak S., Stein K., Kotulska K. Everolimus (RAD001): first systemic treatment for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Fut Oncol 2012, 8:1515-1523.
31. Franz D.N., Leonard J., Tudor C., Chuck G., Care M., Sethuraman G., et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 2006, 59:490-498.
32. Koenig M.K., Butler I.J., Northrup H. Regression of subependymal giant cell astrocytoma with rapamycin in tuberous sclerosis complex. J Child Neurol 2008, 23:1238-1239.
33. Yalon M., Ben-Sira L., Constantini S., Torin A. Regression of subependymal giant cell astrocytomas with RAD001 (Everolimus) in tuberous sclerosis complex. Childs Nerv Syst 2011, 27:179-181.
34. Franz D.N., Agricola K.D., Tudor C.A., Krueger D.A. Everolimus for tumor recurrence after surgical resection for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. J Child Neurol 2013, 28:602-607.
35. Krueger D.A., Care M.M., Holland K., Agricola K., Tudor C., Mangeshkar P., et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010, 363:1801-1811.
36. Wong M. Mammalian target of rapamycin (mTOR) pathways in neurological diseases. Biomed J 2013, 36:40-50.
37. Franz D.N., Belousova E., Sparagana S., Bebin E.M., Frost M., Kuperman R., et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013, 381:125-132.
38. Yalon M., Ben-Sira L., Constantini S., Toren A. Regression of subependymal giant cell astrocytomas with RAD001 (Everolimus) in tuberous sclerosis complex. Childs Nerv Syst 2011, 27:179-181.
39. Perek-Polnik M., Joswiak S., Jurkiewicz E., Perek D., Kotulska K. Effective everolimus treatment of inoperable, life-threatening subependymal giant cell astrocytoma and intractable epilepsy in a patient with tuberous sclerosis complex. Eur J Paediatr Neurol 2012, 16:83-85.
40. Vigliano P., Canavese C., Bobba B., Genitori L., Papalia F., Padovan S., et al. Transmantle dysplasia in tuberous sclerosis: clinical features and surgical outcome in four children. J Child Neurol 2002, 17:752-758.
41. Galluzzi P., Cerase A., Strambi M., Buoni S., Fois A., Venturi C. Hemimegalencephaly in tuberous sclerosis complex. J Child Neurol 2002, 17:677-680.
42. Sakuma H., Iwata O., Sasaki M. Longitudinal MRI findings in a patient with hemimegalencephaly associated with tuberous sclerosis. Brain Dev 2005, 27:458-461.
43. Cartwright M.S., McCarthy S.C., Roach E.S. Hemimegalencephaly and tuberous sclerosis complex. Neurology 2005, 64:1634.
44. Mischel P.S., Nguyen L., Vinters H.V. Cerebral cortical dysplasia associated with pediatric epilepsy. Review of neuropathological features and proposal for a grading system. J Neuropathol Exp Neurol 1995, 54:137-153.
45. Palmini A., Najm I., Avanzini G., et al. Terminology and classification of the cortical dysplasias. Neurology 2004, 62:S2-S8.
46. Krsek P., Maton B., Korman B., Pacheco-Jacome E., Jayakar P., Dunoyer C., et al. Different features of histopathological subtypes of pediatric focal cortical dysplasia. Ann Neurol 2008, 63:758-769.
47. Spreafico R., Blümcke I. Focal cortical dysplasias: clinical implication of neuropathological classification systems. Acta Neuropathol 2010, 120:359-367.
48. Blümcke I., Thom M., Aronica E., Armstrong D.D., Vinters H.V., Palmini A., et al. The clinico-pathological spectrum of Focal Cortical Dysplasias: a consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission. Epilepsia 2011, 52:158-174.
49. Coras R., de Boer O.J., Armstrong D., Becker A., Jacques T.S., Miyata H., et al. Good interobserver and intraobserver agreement in the evaluation of the new ILAE classification of focal cortical dysplasias. Epilepsia 2012, 53:1341-1348.
50. Sarnat H.B., Flores-Sarnat L. Radial micro-columnar cortical architecture: maturational arrest or focal cortical dysplasia?. Pediatr Neurol 2013, 48:259-270.
51. Taylor D.C., Falconer M.A., Bruton C.J., Corsellis J.A., et al. Focal dysplasia of the cerebral cortex in epilepsy. J Neurol Neurosurg Psychiatry 1971, 34:369-387.
52. Barkovich A.J., Kuzniecky R.I., Boller A.W., Grant P.E. Focal transmantle dysplasia in specific malformations of cortical development. Neurology 1997, 49:1148-1152.
53. Luyken C., Blümcke I., Fimmers R., Urbach H., Wiestler O.D., Schramm J. Supratentorial gangliogliomas: histopathological grading and tumor recurrence in 184 patients with a median follow-up of 8years. Cancer 2004, 101:146.
54. Blümcke I., Wiestler O.D. Gangliogliomas: an intriguing tumor entity associated with focal epilepsies. J Neuropathol Exp Neurol 2002, 61:575-584.
55. Najm I.M., Tassi L., Sarnat H.B., Holthausen H., LoRusso G. Epilepsies associated with focal cortical dysplasia. Acta Neuropathol 2014, 128:5-19.
56. Soffer D., Umansky F., Goldman J.E. Ganglioglioma with neurofibrillary tangles (NFTs): neoplastic NFTs share antigenic determinants with NFTs of Alzheimer's disease. Acta Neuropathol 1995, 89:451-453.
57. Brat D.J., Gearing M., Golddthwaite P.T., Wainer B.H., Burger P.C. Tau-associated neuropathology in ganglion cell tumours increases with patient age but appears unrelated to ApoE genotype. Neuropathol Appl Neurobiol 2001, 27:197-205.
58. Prabowo AS, Iyer AM, Veerserma TJ, Anink JJ, Schouten-van Meeteren AYN, Spliet WGM, et al. Expression of neurodegenerative disease-related proteins and caspase-3 in glioneuronal tumours. Neuropathol Appl Neurobiol 2014. doi: 10.1111/nan.12143. (Epub ahead of print).
59. Aronica E., Boer K., Becker A., Redeker S., Spliet W.G.M., van Rijen P.C., et al. Gene expression profile analysis of epilepsy-associated gangliogliomas. Neuroscience 2008, 151:272-292.
60. Barkovich A.J. Pediatric neuroimaging 2005, Lippincott Williams & Wilkins, Philadelphia, p. 362-364. 4th ed.
61. Chappé C., Padovani L., Scavarda D., Forest F., Nanni-Metellus I., Loundou A., et al. Dysembryoplastic neuroepithelial tumors share with pleomorphic xnthoastrocytomas and gangliogliomas BRAFV600E mutation and expression. Brain Pathol 2013, 23:574-583.
62. Elobeid A., Soininen H., Alafuzoff I. Hyperphosphorylated tau in young and middle-aged subjects. Acta Neuropathol 2012, 123:97-104.
63. Gondim D, Murrell J, Oblak A, Sokol D, Walsh L, Bosh G, et al. Childhood neurodegenerative disease with widespread tauopathy. J Neuropathol Exp Neurol 2014;73:624-5 (abstract).
64. Lawler S.E., Senior S., Ingelsson M., Saeki Y., Hyman B.T., Monaco A.E., et al. The HSV-1 iBAC amplicon vector for functional genomics studied into the genetic mechanisms of neurodegenerative disease. Mol Ther 2004, 9:S301-S302.
65. Maas T., Eidenmüller J., Brandt R. Interaction of tau with the neural membrane cortex is regulated by phosphorylation at sites that are modified in paired helical filaments. J Biol Chem 2000, 275:15733-15740.
66. Crino P.B. Molecular pathogenesis of focal cortical dysplasia and hemimegalencephaly. J Child Neurol 2005, 20:330-336.
67. Iqbal K., Liu F., Gong C.-X., Alonso Adel C., Grundke-Iqbal I. Mechanisms of tau-induced neurodegeneration. Acta Neuropathol 2009, 118:53-69.
68. Crino PB. mTOR: a pathogenic signaling pathway in developmental brain malformations. Trends Mol Med 2011;17:734-42.
69. Zilka N., Korenova M., Novak M. Misfolded tau protein and disease modifying pathways in transgenic rodent models of human tauopathies. Acta Neuropathol 2009, 118:71-86.
70. Iqbal K., Liu F., Gong C.-X., del C.Alonso A., Grundke-Iqbal I. Mechanisms of tau-induced neurodegeneration. Acta Neuropathol 2009, 118:53-69.
71. Yamanouchi H., Zhang W., Jay V., Becker L.E. Enhanced expression of microtubule-associated protein-2 in large neurons of cortical dysplasia. Ann Neurol 1996, 39:57-61.
72. Ferrer I., López-González I., Carmona M., Arregui L., Dalfó E., Torrejón-Escribano B., et al. Glial and neuronal tau pathology in tauopathies: characterization of disease-specific phenotypes and tau pathology progression. J Neuropathol Exp Neurol 2014, 73:81-97.
73. McIntosh J.R. Mechanism of mitosis. Trends Biochem Sci 1984, 9:195-198.
74. Wallin M. Microtubules: structural, functional, and clinical aspects. Neuronal and glial proteins: structure, function and clinical application 1988, 321-338. Academic Press, San Diego. P.J. Marangos, I.C. Campbell, R.M. Cohen (Eds.).
75. Pilhofer M., Ladinsky M.S., McDowall A.W., Petroni G., Jensen G.J. Microtubules in bacteria: ancient tubulins build a five-protofilament homolog of the eukaryotic cytoskeleton. PLoS Biol 2011, 9:e1001213.
76. Jessus C., Thibier C., Ozon R. Levels of microtubules during the meiotic maturation of the Xenopus oocyte. J Cell Sci 1987, 87:705-712.
77. Elinson R.P., Rowning B. A transient array of parallel microtubules in frog eggs: potential tracks for a cytoplasmic rotation that specifies the dorso-ventral axis. Dev Biol 1988, 128:185-197.
78. Houliston E, Elinson RP. Microtubules and cytoplasmic reorganization in the frog egg. In: Bearer EL, editor. Current topics in developmental biology, vol. 26. San Diego: Academic Press; 1992. p. 53-70.
79. Sainath R, Gallo G. Cytoskeletal and signaling mechanisms of neurite formation. Cell Tissue Res 2014, in press.
80. Johnson V.E., Stewart W., Smith D.H. Widespread tau and amyloid-beta pathology many years after a single traumatic brain injury in humans. Brain Pathol 2012, 22:142-149.
81. Kang J.H., Vaanderstichele H., Trojanowski J.Q., Shaw L.M. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease. Methods 2012, 56:484-493.
82. Patel S., Lee E.B., Xie S.X., Law A., Jackson E.M., Arnold S.E., et al. Phosphorylated tau/amyloid beta 1-42 ratio in ventricular cerebrospinal fluid reflects outcome in idiopathic normal pressure hydrocephalus. Fluids Barriers CNS 2012, 9:7.
83. Jaworski J., Spangler S., Seeburg D.P., Hoogenraad C.C., Sheng M. Control of dendritic arborization by the phosphoinositide-3'-kinase-Akt-mammalian target of rapamycin pathway. J Neurosci 2005, 25:11300-11312.
84. Dierssen M., Ramakers G.J.A. Dendritic pathology in mental retardation; from molecular genetics to neurobiology. Genes Brain Behav 2006, 5(Suppl. 2):48-60.
85. Sharma A., Hoeffer C.A., Takayhasu Y., Miyawaki T., McBride S.M., Klann E., et al. Dysregulation of mTOR signalling in fragile-X syndrome. J Neurosci 2010, 30:694-702.
86. Troca-Marín J.A., Alves-Sampaio A., Montesinos M.L. An increase in basal BDNF provokes hyperactivation of the Akt-mammalian target of rapamycin pathway and deregulation of local dendritic translation in a mouse model of Down's syndrome. J Neurosci 2011, 31:9445-9455.
87. Hoeffer C.A., Sánchez E., Hagerman R.J., Mu Y., Nguyen D.V., Wong H., et al. Altered mTOR signalling and enhanced CYFIP2 expression levels in subjects with fragile-X syndrome. Gene Brain Behav 2012, 11:332-341.
88. Ruppe V., Dilsiz P., Reiss C.S., Carlson C., Devinsky O., Zagzag D., et al. Developmental brain abnormalities in tuberous sclerosis complex: a comparative tissue analysis of cortical tubers and perituberal cortex. Epilepsia 2014, 55:539-550.
89. Aronica E., Boer K., Baybis M., Yu J., Crino P.B. Co-expression of cyclin D1 and phosphorylated ribosomal S6 proteins in hemimegalencephaly. Acta Neuropathol 2007, 114:287-293.
90. Crino P.B. Focal brain malformations: seizures, signaling, sequencing. Epilepsia 2009, 50(Suppl. 9):3-8.
91. Ljungberg M.C., Bhattacharjee M.B., Lu Y., Armstrong D.L., Yoshor D., Swann J.W., et al. Activation of mammalian target of rapamycin in cytomegalic neurons of human cortical dysplasia. Ann Neurol 2006, 60:420-429.
92. Janota I., Polkey C.E. Cortical dysplasia in epilepsy: a study of material from surgical resections for intractable epilepsy. Recent advances in epilepsy 1992, 37-49. Churchill Livingstone, London, UK. 5th ed. T.A. Pedley, B.S. Meldrum (Eds.).
93. Caviness V.S., Pinto-Lord M.C., Evrard P. The development of laminated patterns in the mammalian neocortex. Morphogenesis and pattern formation 1981, 103-126. Raven Press, New York. G. Connelly (Ed.).
94. Sarnat HB, Flores-Sarnat L. Genetics of epilepsy: morphogenesis timing of genetically-programmed brain malformations in relation to epilepsy. Steinlein O, editor of special issue. Progr Brain Res 2014;213:181-98.
95. Bouchard M., Suchowersky O. Tauopathies: one disease or many?. Can J Neurol Sci 2011, 38:547-556.
96. Niida Y., Stemmer-Rachamimov A.O., Logrip M., Tapon D., Pérez R., Kwiatkowski D.J., et al. Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions. Am J Hum Genet 2001, 69:493-503.
97. Rose V.M., Au K.-S., Pollom G., Roach E.S., Prashner H.R., Northrup H. Germline mosaicism in tuberous sclerosis: how common?. Am J Hum Genet 1999, 64:986-992.
98. Jóźwiak J., Kotulska K., Jóźwiak S. Similarity of balloon cells in focal cortical dysplasia to giant cells in tuberous sclerosis. Epilepsia 2006, 47:805.
99. Kotulska K, Jurkiewicz E, Domańska-Pakiela D, Grajkowska W, Mandera M, Borkowska J, Jóźwiak S. Epilepsy in newborns with tuberous sclerosis complex. Eur J Paediatr Neurol 2014; in press.
100. Becker A.J., Blümcke I., Urbach H., Hans V., Majores M. Molecular neuropathology of epilepsy-associated glioneuronal malformations. J Neuropathol Exp Neurol 2006, 65:99-108.
101. Aronica E., Crino P.B. Epilepsy related to developmental tumors and malformations of cortical development. Neurotherapeutics 2014, 11:251-268.
102. Cepeda C., André V.M., Levine M.S., Salamon N., Miyata H., Vinters H.V., et al. Epileptogenesis in pediatric cortical dysplasia: the dysmature cerebral developmental hypothesis. Epilepsy Behav 2006, 9:219-235.
103. Tang S.J., Reis G., Kang H., Gingras A.C., Sonenberg N., Schuman E.M. A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus. Proc Natl Acad Sci U S A 2002, 99:467-472.
104. Bourgeois J.P. Synaptogenèse et epigenèse cerebrales [Brain synaptogenesis and epigenesist]. Med Sci (Paris) 2005, 21:428-433.
105. Cepeda C., André V.M., Yamazaki I., Hauptman J.S., Chen J.Y., Vinters H.V., et al. Comparative study of cellular and synaptic abnormalities in brain tissue samples from pediatric tuberous sclerosis complex and cortical dysplasia type II. Epilepsia 2010, 51(Suppl. 3):160-165.
106. Stoica L., Zhu P.J., Huang W., Zhou H., Kozma S.C., Costa-Mattioli M. Selective pharmacogenetic inhibition of mammalian target of Rapamycin complex1 (mTORC1) blocks long-term synaptic plasticity and memory storage. Proc Natl Acad Sci U S A 2011, 108:3791-3796.
107. Iver A., Prabowo A., Aninnk J., Spliet W.G., van Rijen P.C., Aronica E. Cell injury and premature neurodegeneration in focal malformations of cortical development. Brain Pathol 2014, 24:1-17.
108. Holth J.K., Bomben V.C., Reed J.G., Inoue T., Younkin L., Younkin S.G., et al. Tau loss attenuates neuronal network hyperexcitability in mouse and Drosophila genetic models of epilepsy. J Neurosci 2013, 33:1651-1659.
109. Xi Z.-Q., Wang X.F., Shu X.F., Chen G.J., Xiao F., Sun J.J., et al. Is intractable epilepsy a tauopathy?. Med Hypotheses 2011, 76:897-900.